This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xue, D. Articles by Buchan, A. M. Search for Related Content PubMed PubMed Citation Articles by Xue, D. Articles by Buchan, A. M.

Stroke, Vol 23, 894-899, Copyright © 1992 by American Heart Association

ARTICLES

Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats

D Xue, A Slivka and AM Buchan
Department of Neurology and Neuroscience, Ottawa Civic Hospital, Ontario, Canada.

BACKGROUND AND PURPOSE: We examined the cytoprotective effect of the lipid peroxidation inhibitor tirilazad mesylate (U74006F) in rodent models of neocortical infarction induced by transient and permanent focal cerebral ischemia. METHODS: Wistar rats (experiment 1) and spontaneously hypertensive rats (experiment 2) were subjected to 2 hours of transient middle cerebral artery occlusion followed by 22 hours of reperfusion and pretreated with 10 mg/kg i.p. tirilazad, vehicle, or saline. Repeat doses were given at 4 and 10 hours after reperfusion. Spontaneously hypertensive rats were also subjected to permanent middle cerebral artery occlusion and either pretreated with tirilazad, vehicle, or saline intraperitoneally (experiment 3) or treated with either tirilazad or vehicle intravenously after ischemia (experiment 4). Cortical infarct volumes were measured 24 hours after the onset of either transient or permanent ischemia, and changes in core regional cerebral blood flow were monitored with laser Doppler flowmetry. RESULTS: Tirilazad reduced infarct volume after transient ischemia by 40% in Wistar rats (p = 0.08) (experiment 1) and 23% in spontaneously hypertensive rats (p less than 0.05) (experiment 2) but did not reduce infarction after permanent ischemia whether it was given intraperitoneally (experiment 3) or intravenously (experiment 4). Ischemic core blood flows were not affected during ischemia, nor were they affected during reperfusion after transient ischemia. CONCLUSIONS: Tirilazad reduces cortical infarction in transient but not permanent ischemia, an effect not related to improvement in regional cerebral blood flow. Tirilazad might prove to be useful as an adjuvant therapy after successful thrombolysis in acute stroke patients.

This article has been cited by other articles:

				E. Sena, P. Wheble, P. Sandercock, and M. Macleod Systematic Review and Meta-Analysis of the Efficacy of Tirilazad in Experimental Stroke Stroke, February 1, 2007; 38(2): 388 - 394. [Abstract] [Full Text] [PDF]

				S. Zausinger, K. Scholler, N. Plesnila, and R. Schmid-Elsaesser Combination Drug Therapy and Mild Hypothermia After Transient Focal Cerebral Ischemia in Rats Stroke, September 1, 2003; 34(9): 2246 - 2251. [Abstract] [Full Text] [PDF]

				C. P. Derdeyn, J. D. Barr, A. Berenstein, John. J. Connors, J. E. Dion, G. R. Duckwiler, R. T. Higashida, C. M. Strother, T. A. Tomsick, and P. Turski The International Subarachnoid Aneurysm Trial (ISAT): A Position Statement from the Executive Committee of the American Society of Interventional and Therapeutic Neuroradiology and the American Society of Neuroradiology AJNR Am. J. Neuroradiol., August 1, 2003; 24(7): 1404 - 1408. [Full Text] [PDF]

				Y. Gilgun-Sherki, Z. Rosenbaum, E. Melamed, and D. Offen Antioxidant Therapy in Acute Central Nervous System Injury: Current State Pharmacol. Rev., June 1, 2002; 54(2): 271 - 284. [Abstract] [Full Text] [PDF]

				R. J. Kavanagh and P. C. A. Kam Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119. [Abstract] [Full Text] [PDF]

				R. Schmid-Elsaesser, E. Hungerhuber, S. Zausinger, A. Baethmann, H.-J. Reulen, and J. A. Zivin Combination Drug Therapy and Mild Hypothermia : A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia • Editorial Comment: A Promising Treatment Strategy for Reversible, Focal Cerebral Ischemia Stroke, September 1, 1999; 30 (9): e1891 - 1899. [Abstract] [Full Text] [PDF]

				R. Schmid-Elsaesser, S. Zausinger, E. Hungerhuber, N. Plesnila, A. Baethmann, and H.-J. Reulen Superior Neuroprotective Efficacy of a Novel Antioxidant (U-101033E) With Improved Blood-Brain Barrier Permeability in Focal Cerebral Ischemia Stroke, October 1, 1997; 28(10): 2018 - 2024. [Abstract] [Full Text]

				E. D. Hall, P. K. Andrus, S. L. Smith, T. J. Fleck, H. M. Scherch, B. S. Lutzke, G. A. Sawada, J. S. Althaus, P. F. Vonvoigtlander, G. E. Padbury, et al. Pyrrolopyrimidines: Novel Brain-Penetrating Antioxidants with Neuroprotective Activity in Brain Injury and Ischemia Models J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 895 - 904. [Abstract] [Full Text]

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				T. B. Muller, O. Haraldseth, R. A. Jones, G. Sebastiani, C. F. Lindboe, G. Unsgard, and A. N. Oksendal Perfusion and Diffusion-Weighted MR Imaging for In Vivo Evaluation of Treatment With U74389G in a Rat Stroke Model Stroke, August 1, 1995; 26(8): 1453 - 1458. [Abstract] [Full Text]

				M. D. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II Neuroscientist, May 1, 1995; 1(3): 164 - 175. [Abstract] [PDF]

				A. Olah, A. C. Cernaianu, T. Gaprindashvili, J. H. Cilley JR, M. M. Neuwirth, N. Ansari, and A. J. DelRossi Improvement of Spinal Cord Electrical Activity with Lazaroid (U74006F) During Operations on the Thoracic Aorta: Evaluation of a Novel Lipid Peroxidation Inhibitor Vascular and Endovascular Surgery, July 1, 1994; 28(6): 377 - 381. [Abstract] [PDF]